Get the Stockscreener App
27.44
1.61%
-0.45
After Hours:
26.74
-0.70
-2.55%
Celldex Therapeutics Inc stock is traded at $27.44, with a volume of 328.62K.
It is down -1.61% in the last 24 hours and up +2.16% over the past month.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.
See More
Previous Close:
$27.89
Open:
$27.82
24h Volume:
328.62K
Relative Volume:
0.30
Market Cap:
$1.82B
Revenue:
$9.98M
Net Income/Loss:
$-154.08M
P/E Ratio:
-10.39
EPS:
-2.64
Net Cash Flow:
$-159.66M
1W Performance:
+1.55%
1M Performance:
+2.16%
6M Performance:
-19.81%
1Y Performance:
-6.38%
1-Day Range:
$27.02
$27.82
1-Week Range:
$26.53
$28.40
52-Week Range:
$22.93
$53.18
Celldex Therapeutics Inc Stock (CLDX) Company Profile
Name
Celldex Therapeutics Inc
Sector
Industry
Phone
908-200-7500
Address
53 FRONTAGE ROAD, HAMPTON
Compare CLDX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLDX
Celldex Therapeutics Inc
|
27.44 | 1.82B | 9.98M | -154.08M | -159.66M | -2.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.13 | 120.56B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
750.22 | 82.44B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
616.55 | 36.87B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.07 | 32.64B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.39 | 28.38B | 3.30B | -501.07M | 1.03B | -2.1146 |
Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-07-24 | Initiated | Citigroup | Buy |
| Sep-30-24 | Initiated | Goldman | Neutral |
| Sep-27-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jun-18-24 | Initiated | Stifel | Buy |
| Jun-11-24 | Initiated | Wolfe Research | Outperform |
| Dec-20-23 | Initiated | TD Cowen | Outperform |
| Nov-10-23 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Aug-22-23 | Initiated | Wells Fargo | Underweight |
| Sep-17-21 | Initiated | Jefferies | Buy |
| Sep-10-21 | Initiated | SVB Leerink | Outperform |
| Jul-22-21 | Initiated | Guggenheim | Buy |
| Feb-21-20 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-01-17 | Resumed | H.C. Wainwright | Buy |
| Nov-07-16 | Initiated | Aegis Capital | Buy |
| Mar-08-16 | Downgrade | Jefferies | Buy → Hold |
| Mar-07-16 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-07-16 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| Mar-07-16 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-01-16 | Initiated | H.C. Wainwright | Buy |
| Aug-11-15 | Reiterated | Brean Capital | Buy |
| Aug-11-15 | Reiterated | Oppenheimer | Outperform |
| Aug-11-15 | Reiterated | ROTH Capital | Buy |
| Jun-02-15 | Reiterated | WBB Securities | Strong Buy |
| Nov-17-14 | Reiterated | ROTH Capital | Buy |
| Mar-04-14 | Reiterated | Oppenheimer | Outperform |
| Jul-08-13 | Reiterated | Cantor Fitzgerald | Buy |
| Mar-08-13 | Reiterated | Cantor Fitzgerald | Buy |
| Feb-26-13 | Reiterated | Oppenheimer | Outperform |
| Jan-10-13 | Reiterated | Cantor Fitzgerald | Buy |
| Oct-02-12 | Reiterated | Oppenheimer | Outperform |
| Sep-14-12 | Reiterated | Cantor Fitzgerald | Buy |
View All
Celldex Therapeutics Inc Stock (CLDX) Latest News
Intech Investment Management LLC Makes New $871,000 Investment in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - MarketBeat
Fisher Asset Management LLC Purchases 253,808 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) - MarketBeat
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Shares Sold by Algert Global LLC - MarketBeat
Chronic Spontaneous Urticaria Pipeline Therapeutics Assessment Report 2024 (Updated) - openPR
Celldex Therapeutics' SWOT analysis: barzolvolimab stock shows promise in urticaria treatment - Investing.com
Celldex Therapeutics’ (CLDX) “Buy” Rating Reiterated at HC Wainwright - Defense World
HC Wainwright Has Positive Forecast for CLDX FY2025 Earnings - MarketBeat
Jennison Associates LLC Raises Stock Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - MarketBeat
Insider Spends US$308k Buying More Shares In Celldex Therapeutics - Simply Wall St
Celldex Therapeutics (NASDAQ:CLDX) Earns "Buy" Rating from HC Wainwright - MarketBeat
Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases - The Manila Times
Celldex Launches Phase 1 Trial of Novel Dual-Action Inflammatory Disease Treatment | CLDX Stock News - StockTitan
Beyond The Numbers: 11 Analysts Discuss Celldex Therapeutics Stock - Benzinga
Celldex Therapeutics Reports Q3 2024 Progress and Financials - TipRanks
Celldex Therapeutics (NASDAQ:CLDX) Sets New 12-Month LowWhat's Next? - MarketBeat
Celldex stock touches 52-week low at $24.41 amid market shifts - Investing.com Canada
Steven Cohen's Strategic Reduction in Celldex Therapeutics Holdi - GuruFocus.com
Eventide Asset Management's Strategic Acquisition in Celldex The - GuruFocus.com
Celldex Therapeutics' SWOT analysis: barzolvolimab stock potential in urticaria treatment - Investing.com India
Polar Capital Holdings Plc Reduces Stake in Celldex Therapeutics Inc - GuruFocus.com
Insider Buying: Celldex Therapeutics Inc (CLDX) President & CEO Acquires Shares - GuruFocus.com
FMR LLC's Strategic Reduction in Celldex Therapeutics Inc Shares - GuruFocus.com
Celldex Therapeutics (NASDAQ:CLDX) Trading 4.2% Higher Following Insider Buying Activity - Defense World
Insider Buying: Celldex Therapeutics, Inc. (NASDAQ:CLDX) CEO Buys 11,500 Shares of Stock - MarketBeat
Celldex Therapeutics CEO Anthony Marucci buys $308,430 in stock - Investing.com
Celldex Therapeutics to Present at Upcoming Investor Conferences - The Manila Times
Celldex (CLDX) to Present at Two Major Healthcare Investor Conferences in Q4 | CLDX Stock News - StockTitan
Leerink Partnrs Analysts Lower Earnings Estimates for CLDX - MarketBeat
What is HC Wainwright's Estimate for CLDX FY2024 Earnings? - MarketBeat
HC Wainwright Reiterates “Buy” Rating for Celldex Therapeutics (NASDAQ:CLDX) - Defense World
Wellington Management Group LLP's Strategic Acquisition in Celld - GuruFocus.com
FY2028 Earnings Forecast for CLDX Issued By Leerink Partnrs - MarketBeat
Celldex Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Celldex drops phase 1 tumor bispecific to focus on inflammation - Fierce Biotech
Celldex Therapeutics (CLDX) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Celldex: Q3 Earnings Snapshot - San Antonio Express-News
Celldex Reports Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times
Celldex Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Celldex stock touches 52-week low at $25.04 amid market shifts By Investing.com - Investing.com South Africa
Celldex Therapeutics (NASDAQ:CLDX) Reaches New 12-Month LowTime to Sell? - MarketBeat
Celldex stock touches 52-week low at $25.04 amid market shifts - Investing.com India
Celldex Therapeutics' Strong Cash Runway Supports Barzolvolimab's Path To Market - Seeking Alpha
Urticaria Clinical Trial Pipeline Accelerates: 20+ Leading Companies Pioneering New Treatments | DelveInsight - GlobeNewswire
Urticaria Clinical Trial Pipeline Accelerates: 20+ Leading Companies Pioneering New Treatments | DelveInsight - GlobeNewswire Inc.
Emerald Advisers LLC Has $15.51 Million Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - MarketBeat
Evommune raises $115M to accelerate immune drug tests - Yahoo Finance
Market reaction to Intellia data suggests perfection remains bar for gene editing - BioCentury
Celldex Therapeutics Inc Stock (CLDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.61%
1.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):